Merck & Co., Inc.

Equities

Market Closed - Nyse Other stock markets 21:02:03 09/04/2026 BST			5-day change	1st Jan Change
122.68 ^USD	-0.41%		+1.50%	+16.55%

04-09	Biopharma Stocks Largely Exempt From Pharma Tariffs, BofA Says	MT
04-08	Merck CEO Pay Falls 10% in 2025 Due to Lower Stock, Option Awards	DJ

Published on 06/10/2025 at 04:35 pm BST - Modified on 06/10/2025 at 06:05 pm BST

S&P Capital IQ

Presenter Speech
Unknown Analyst (Analysts)

Let's get started. Very excited to welcome Merck to our next session, Rob Davis, Chairman and CEO; Dean Li, EVP and President of Merck Research Labs.

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

04-09	Biopharma Stocks Largely Exempt From Pharma Tariffs, BofA Says	MT
04-08	Merck CEO Pay Falls 10% in 2025 Due to Lower Stock, Option Awards	DJ
04-08	Merck & Co Inc CEO Robert M. Davis 2025 total compensation $20.8 million	RE
04-08	Wolfe Research Adjusts PT on Merck & Co. to $150 From $142, Maintains Outperform Rating	MT
04-07	Merck Begins $53 Per Share Tender Offer for Terns Pharmaceuticals	MT
04-07	Merck begins tender offer to acquire Terns Pharmaceuticals, Inc.	RE
04-06	JPMorgan Adjusts Price Target on Merck & Co. to $135 From $125, Maintains Overweight Rating	MT
04-02	Merck Announces European Commission Approves KEYTRUDA (pembrolizumab) Plus Paclitaxel ± Bevacizumab for the Treatment of Adults With PD-L1 (CPS =1) Platinum-Resistant Recurrent Ovarian Carcinoma	CI
04-02	Merck Announces Initiation of Pivotal Phase 2B/3 Trial Evaluating Mk-8748 for Treatment of Neovascular Age-Related Macular Degeneration	CI
04-02	Merck Says EU Approves Keytruda Combination Regimen for Platinum-Resistant Ovarian Cancer	MT
04-02	Merck Starts Phase 2b/3 Trial of Neovascular Age-Related Macular Degeneration Treatment	MT
04-02	US Set to Impose 100% Tariffs on Some Drug Imports	MT
04-01	Trump administration readies new tariffs on select drugmakers, Bloomberg News reports	RE
03-31	Infinimmune, Merck enter into antibody discovery pact	RE
03-31	Infinimmune enters collaboration with Merck to discover novel human antibody therapeutics	RE